Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07054593

Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan

This study is designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Silicon Valley Gastroenterology

Mountain View, California, 94040, United States

About this study

Prospective, open-label, single-arm, non-randomized, single-center study designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet all of the following criteria to be included in the study:

  • Males or females 18 years of age or older and 85 years of age or younger at the time of the first Screening Visit.
  • ASA Classification 1 or 2.
  • For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit. Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).
  • Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.

Exclusion criteria

Subjects with any of the following conditions or characteristics must be excluded from the study:

  • History of any of the following:
  • prior gastric or esophageal surgery, including bariatric surgery
  • bowel obstruction
  • gastric outlet obstruction
  • gastroparesis
  • acute diverticulitis
  • inflammatory bowel disease
  • ileostomy or colostomy
  • gastric or esophageal cancer
  • achalasia
  • active dysphagia or odynophagia
  • Daily PPI use in the last 30 days
  • Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding
  • Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study
  • A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the subject while involved in the study

Treatment and study plan

CapScan

Device

Gut sampling capsule

Primary outcomes

  1. Identification of the gut microbial taxa using DNA sequencing of the samples obtained from the CapScan devices

    Time frame: 2 months

    A primary endpoint is to identify and quantitate the relative abundance of the gut microbial taxa using at least 3 million metagenomic DNA sequencing reads in at least 75% of the samples obtained from the CapScan devices.

  2. Identification of the gut metabolites using liquid chromatography - mass spectrometry of the samples obtained from the CapScan devices

    Time frame: 2 months

    A primary endpoint is to identify at least 1,500 annotated gut metabolites from the intestinal tract in at least 75% of the samples obtained from the CapScan devices.

Secondary outcomes

  1. Detect changes in composition of gut microbial taxa using DNA sequencing in subjects before and after omeprazole treatment

    Time frame: 2 months

    Evaluate the diversity, centroids and distributions of microbial taxa from sequenced CapScan samples of the study population from before and after omeprazole treatment.

  2. Detect changes in composition of gut metabolites using liquid chromatography - mass spectrometry in subjects before and after omeprazole treatment

    Time frame: 2 months

    Evaluate the diversity, centroids and distributions of gut metabolites in CapScan samples of the study population from before and after omeprazole treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Taufui

CONTACT

[email protected]

650-988-7530

Sponsors and collaborators

Lead sponsor

Envivo Bio Inc

Industry

Registry information

Official study title

An Open-Label, Pilot Study Designed To Evaluate The Effect Of A Proton Pump Inhibitor On The Regional Composition Of The Gut Microbiota And Metabolic Profiles Of Health Volunteers Using The Capscan® Samplng Capsule

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 8, 2025
Registry last updated
Jul 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.